Botulinum toxin injections may ease low back pain

May 21, 2001

ST. PAUL, MN - Help may be on the way for sufferers of chronic low back pain. Injections of botulinum toxin A, a drug based on the bacteria that causes food poisoning, eased the pain for patients in a study published in the May 22 issue of Neurology, the scientific journal of the American Academy of Neurology.

"More studies need to be done because we looked at only a small number of patients, but these results are promising for people with this problem," said study author and neurologist Bahman Jabbari, MD, of Walter Reed Army Medical Center in Washington, D.C.

Chronic low back pain costs an estimated 50 billion dollars per year to the U.S. economy, according to the study.

For the randomized, double-blind study, 31 patients with chronic low back pain were given injections of either botulinum toxin or a saline solution. The patients had experienced pain for at least six months, with an average of six years.

Three weeks after the injections, 73 percent of the people who received the drug said the amount of pain they were experiencing had gone down by 50 percent or more, compared to 25 percent of those who received the saline.

After eight weeks, 60 percent of those who received the drug still said their pain had gone down by 50 percent or more, compared to 13 percent of those receiving saline.

The patients also took a questionnaire before the study and after eight weeks that measured their ability to perform activities of daily life, such as walking, lifting and traveling. After eight weeks, 67 percent of the patients who received botulinum toxin showed improvement in their ability to function, compared to 19 percent of those who received saline.

None of the patients reported any side effects from the injections.

None of the patients who received botulinum toxin reported any worsening of pain or function after the injection. Two patients reported worsening of pain after the saline injection.

Six of the 10 people who received botulinum toxin were re-evaluated after six months. They reported that the drug's effect wore off after three to four months.

Before the study started, the patients were taking a variety of analgesic and anti-spasmodic drugs, including baclofen, non-steroidal anti-inflammatory drugs, anti-depressants and muscle relaxants. They were advised to continue their medications and not to change the dosage during the study.

Researchers aren't sure how the botulinum toxin works to reduce the pain; several factors may be contributing. The drug reduces the amount and severity of muscle spasms. It may also reduce pain by decreasing the input from sensory fibers or by acting on pain receptors, Jabbari said. Jabbari said more studies also need to be done to determine whether the drug will continue to help patients after repeated injections.

"That has been the case for patients who receive botulinum toxin injections for other disorders, such as the muscle disorders dystonia and spasticity, so hopefully that will be true for people with low back pain as well," he said.
A neurologist is a medical doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system.

The American Academy of Neurology, an association of more than 17,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research.

For more information about the American Academy of Neurology, visit its web site at

For more information contact:
Kathy Stone, 651-695-2763

American Academy of Neurology

Related Pain Articles from Brightsurf:

Pain researchers get a common language to describe pain
Pain researchers around the world have agreed to classify pain in the mouth, jaw and face according to the same system.

It's not just a pain in the head -- facial pain can be a symptom of headaches too
A new study finds that up to 10% of people with headaches also have facial pain.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

The insular cortex processes pain and drives learning from pain
Neuroscientists at EPFL have discovered an area of the brain, the insular cortex, that processes painful experiences and thereby drives learning from aversive events.

Pain, pain go away: new tools improve students' experience of school-based vaccines
Researchers at the University of Toronto and The Hospital for Sick Children (SickKids) have teamed up with educators, public health practitioners and grade seven students in Ontario to develop and implement a new approach to delivering school-based vaccines that improves student experience.

Pain sensitization increases risk of persistent knee pain
Becoming more sensitive to pain, or pain sensitization, is an important risk factor for developing persistent knee pain in osteoarthritis (OA), according to a new study by researchers from the Université de Montréal (UdeM) School of Rehabilitation and Hôpital Maisonneuve Rosemont Research Centre (CRHMR) in collaboration with researchers at Boston University School of Medicine (BUSM).

Becoming more sensitive to pain increases the risk of knee pain not going away
A new study by researchers in Montreal and Boston looks at the role that pain plays in osteoarthritis, a disease that affects over 300 million adults worldwide.

Pain disruption therapy treats source of chronic back pain
People with treatment-resistant back pain may get significant and lasting relief with dorsal root ganglion (DRG) stimulation therapy, an innovative treatment that short-circuits pain, suggests a study presented at the ANESTHESIOLOGY® 2018 annual meeting.

Sugar pills relieve pain for chronic pain patients
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology.

Peripheral nerve block provides some with long-lasting pain relief for severe facial pain
A new study has shown that use of peripheral nerve blocks in the treatment of Trigeminal Neuralgia (TGN) may produce long-term pain relief.

Read More: Pain News and Pain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to